Tuesday, March 17, 2026

9·19 Military Agreement Revival: Can South Korea Lead Amid North’s Hostility?

The Lee administration aims to restore the September 19 inter-Korean military agreement to prevent clashes and build trust amid rising tensions.

US Senate Passes NDAA Limiting USFK Reduction, Trump Signature Pending

The U.S. Senate passed the NDAA for FY2026, limiting troop reductions in South Korea and allocating $901 billion for defense.

How the New U.S. Investment Special Law Could Shield South Korea from Tariff Threats

Kim Sang-hoon predicts the U.S. Investment Special Act will stabilize tariffs, enhancing investment and cooperation between Korea and the U.S.

Tag: pharmaceutical

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

SK Chemicals’ Joins Tablet Surpasses 700 Billion KRW in Sales… What’s Behind the Osteoarthritis Drug’s Success?

SK Chemicals' Joins Tablets, a natural osteoarthritis treatment, surpasses 700 billion KRW in sales, marking a significant milestone in Korea.

Korea’s Olive Young Gets a New Sleep Aid: Daewon Launches Honey Sleep Shot Backed by a Study

Daewon Health launches Honey Sleep Shot, a plant-based sleep aid, in 900 Olive Young stores, targeting sleep issues for modern consumers.

Hemlibra Breakthrough: 91% of Hemophilia Patients in Japan Experience No Adverse Reactions!

JW Pharmaceutical's Hemlibra shows 91% safety in Japanese hemophilia patients, with no adverse reactions in long-term study.

Brivaracetam vs. Levetiracetam: Which Epilepsy Drug Offers Better Safety and Efficacy?

Samjin Pharmaceutical launches Bricetam Tablets, improving epilepsy treatment with fewer side effects and better adherence for patients.

A New Hair-Growth Pathway?: JW0061 Targets GFRA1 After 7.2x Organoid Results and a 39% Animal Boost

JW Pharmaceutical's hair loss treatment JW0061 gains FDA approval for clinical trials, promising innovative growth stimulation for men and women.

JW Pharmaceutical Advances Gout Treatment with Epaminurad

JW Pharmaceutical advances its gout treatment, Epaminurad, with global trials nearing completion and U.S. patent secured for market entry.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

2025’s Drug Price Revolution: What Asian Pharma Firms Need to Know About MFN Policies

Trump's second term sees U.S. drug pricing reforms and supply chain shifts, prompting South Korean firms to seize new opportunities.

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.